Latest research on G-CSF

Filgrastim is a recombinant, non-pegylated human granulocyte colony stimulating factor (G-CSF) analogue manufactured by recombinant DNA technology using a strain of E. coli. It is marketed as the brand name Neupogen by Amgen. Chemically, it consists of 175 amino acid residues. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine necessary for expression in E coli. Tbo-filgrastim, which is marketed by Sicor Biotech and FDA approved on August 29, 2012, contains the same active ingredient as Neupogen and is biologically similar, but it is formulated to be short-acting. On March 6, 2015, the FDA approved the biosimilar Zarxio (filgrastim-sndz) and is indicated for use in the same conditions as Neupogen. Zarxio is marketed by Sandoz.

Latest findings

Patients received their current standard treatment which was supplemented only by administration of filgrastim (Neupogen, Amgen) at the following doses: 5 μg/kg of body weight/day for five consecutive days (course 1). [source, 2016]
The study was performed by the Helsinki Declaration and was approved by the Ethical Committee of the University of Las Palmas de Gran Canaria (CEIH-2010-01 and CEIH-2009-01). [source, 2016]
Oxygen uptake was measured with a metabolic cart (Vmax N29; Sensormedics, Yorba Linda, California, USA), calibrated before each test according to the manufacturer instructions, with high-grade calibration gasses (Carburos Metálicos, Las Palmas de Gran Canaria, Spain). [source, 2016]
The research protocol was revised and authorized by the Ethical Committee of Animal Welfare (CEBA) of the University of Las Palmas de Gran Canaria. [source, 2016]
This is reversible by the administration of Granulocyte Colony Stimulating Factor (G-CSF) which leads to blood cell viral DNA becoming detectable within 6 days of administration. [source, 2016]
The aims of this study were to analyze the causes of stranding in a large population of loggerhead turtles admitted to the Tafira Wildlife Rehabilitation Center (TWRC) in Gran Canaria Island, Spain, from 1998 to 2014 using specific epidemiological data, to compare these results with those obtained in other geographic regions, and to analyze the outcomes of the rehabilitation process to allow meaningful auditing of its quality. [source, 2016]
Guacimara Medina), and the Environment Department of the Cabildo de Gran Canaria (Ms. [source, 2016]
Animal work and all sampling procedures were specifically approved by the TWRC Animal Care Committee and the insular government Cabildo de Gran Canaria, and were consistent with standard vertebrate protocols and veterinary practices. [source, 2016]
A retrospective study was performed using the Original medical records of 1,860 loggerhead turtles admitted to the TWRC, Gran Canaria Island, Spain, from 1998 to 2014. [source, 2016]
The TWRC receives turtles stranded in Gran Canaria and eventually from other islands of the Canary Islands archipelago. [source, 2016]